Candel Therapeutics (CADL) Operating Expenses: 2020-2023
Historic Operating Expenses for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to $10.3 million.
- Candel Therapeutics' Operating Expenses rose 26.88% to $10.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $38.4 million, marking a year-over-year increase of 10.18%. This contributed to the annual value of $33.4 million for FY2024, which is 13.08% down from last year.
- Per Candel Therapeutics' latest filing, its Operating Expenses stood at $10.3 million for Q4 2023, which was up 16.44% from $8.9 million recorded in Q3 2023.
- In the past 5 years, Candel Therapeutics' Operating Expenses registered a high of $10.3 million during Q4 2023, and its lowest value of $2.4 million during Q2 2020.
- Its 3-year average for Operating Expenses is $8.3 million, with a median of $8.8 million in 2022.
- In the last 5 years, Candel Therapeutics' Operating Expenses surged by 189.93% in 2021 and then decreased by 0.57% in 2023.
- Candel Therapeutics' Operating Expenses (Quarterly) stood at $6.2 million in 2020, then rose by 26.23% to $7.8 million in 2021, then increased by 4.65% to $8.1 million in 2022, then rose by 26.88% to $10.3 million in 2023.
- Its last three reported values are $10.3 million in Q4 2023, $8.9 million for Q3 2023, and $9.6 million during Q2 2023.